The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice

References

• Prevention, C.f.D.C.a., National Diabetes Statistics Report, 2017. Atlanta, GA Centers for Disease Control and Prevention, US Department of Health and Human Services. 2017.
   Google Scholar
• Salles GF, Bloch KV, Cardoso CR. Mortality and predictors of mortality in a cohort of Brazilian type 2 diabetic patients. Diabetes Care. 2004;27(6):1299–1305.
   Web of Science ®Google Scholar
• Rossing P, Breum L, Major-Pedersen A, et al. Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. Diabet Med. 2001;18(3):199–205.
   Web of Science ®Google Scholar
• Cohen IS, Lin RZ, Ballou LM. Acquired long QT syndrome and phosphoinositide 3-kinase. Trends Cardiovasc Med. 2017;27(7):451–459.
   Web of Science ®Google Scholar
• Naas AA, Davidson NC, Thompson C, et al. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. BMJ. 1998;316(7133):745–746.
   Google Scholar
• Veglio M, Giunti S, Stevens LK, et al. Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia : the EURODIAB IDDM complications study group. Diabetes Care. 2002;25(4):702–707.
   Web of Science ®Google Scholar
• Giunti S, Bruno G, Lillaz E, et al. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2007;30(8):2057–2063.
   Web of Science ®Google Scholar
• Li X, et al. Prevalence and risk factors of prolonged QTc interval among Chinese patients with type 2 diabetes. Exp Diabetes Res. 2012;2012:234084.
   Google Scholar
• Lu Z, et al. Prevalence of QT prolongation and associated LVEF changes in diabetic patients over a four-year retrospective time period. J Community Hosp Intern Med Perspect. 2017;7(2):87–94.
   PubMed Web of Science ®Google Scholar
• Fruman DA, et al. The PI3K Pathway in Human Disease. Cell. 2017;170(4):605–635.
   PubMed Web of Science ®Google Scholar
• Lu Z, Wu C-YC, Jiang Y-P, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4(131):131ra50.
   Web of Science ®Google Scholar
• Lu Z, Jiang Y-P, Wu C-YC, et al. Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart. Diabetes. 2013;62(12):4257–4265.
   Web of Science ®Google Scholar
• Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J Med. 2018;379(21):2052–2062.
   PubMed Web of Science ®Google Scholar
• Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card Electrophysiol Clin. 2015;7(2):341–355.
   Google Scholar
• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–1467.
   PubMed Web of Science ®Google Scholar
• Molnar J, Weiss J, Zhang F, et al. Evaluation of five QT correction formulas using a software-assisted method of continuous QT measurement from 24-hour Holter recordings. Am J Cardiol. 1996;78(8):920–926.
   Web of Science ®Google Scholar
• Trinkley KE, Lee Page R, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–1726.
   PubMed Web of Science ®Google Scholar
• Li EC, Esterly JS, Pohl S, et al. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy. 2010;30(7):684–701.
   Web of Science ®Google Scholar
• Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011–1016.
   PubMed Web of Science ®Google Scholar
• Rautaharju PM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982–991.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33(35):4210–4218.
   PubMed Web of Science ®Google Scholar
• Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160–3167.
   Web of Science ®Google Scholar
• Lu Z, Jiang Y-P, Xu X-H, et al. Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling. Diabetes. 2007;56(11):2780–2789.
   Web of Science ®Google Scholar
• Agrawal M, Garg RJ, Cortes J, et al. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep. 2010;5(2):70–80.
   Web of Science ®Google Scholar
• Coppola C, Rienzo A, Piscopo G, et al. Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135–143.
   PubMed Web of Science ®Google Scholar
• Veglio M, Borra M, Stevens LK, et al. The relation between QTc interval prolongation and diabetic complications. the EURODIAB IDDM complication study group. Diabetologia. 1999;42(1):68–75.
   Web of Science ®Google Scholar
• Kobayashi S, Nagao M, Asai A, et al. Severity and multiplicity of microvascular complications are associated with QT interval prolongation in patients with type 2 diabetes. J Diabetes Investig. 2018;9(4):946–951.
   Web of Science ®Google Scholar
• Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013;36(6):413–426.
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on qt interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38(8):693–710.
   PubMed Web of Science ®Google Scholar
• Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol. 2010;6(10):1175–1193.
   PubMed Web of Science ®Google Scholar
• Cooper S, Sandhu H, Hussain A, et al. Ageing alters the severity of Sunitinib-induced cardiotoxicity: investigating the mitogen activated kinase kinase 7 pathway association. Toxicology. 2019;411:49–59.
   Web of Science ®Google Scholar
• Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26(11):643–656.
   PubMed Web of Science ®Google Scholar
• Semeraro F, et al. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060.
   PubMed Web of Science ®Google Scholar
• Stark AK, Sriskantharajah S, Hessel EM, et al. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82–91.
   PubMed Web of Science ®Google Scholar
• Lamore SD, Kohnken RA, Peters MF, et al. Cardiovascular Toxicity Induced by Kinase Inhibitors: mechanisms and Preclinical Approaches. Chem Res Toxicol. 2020;33(1):125–136.
   PubMed Web of Science ®Google Scholar